Do we know what is the net cash in Adcock Ingram's books?
And sir, the court case that we've done is to prevent them from ever winning the patent? Or why are we spending money on stopping? There are so many other companies that also have got approval from the SEZ. What's the logic behind it?
Sir, this other operating expenses, other expenses have increased disproportionately this year. We had a policy of doing something like 8% of the top line, and you have said high-value R&D expenditure, it's happening for the last, I think, 24 months. Sir, can we not get any color on where we are researching, what we are doing, where will we see the impact? Investors -- shareholders need to know what is there next year, next to next year, sir, beyond the semaglutide because Revlimid is history now, we have made a lot of money. That is my first question, sir. Where are we researching...
Sir, the follow-up on this -- so as in, like, you are not getting deterred by all these tariffs. You're still targeting Para IV filings only. I mean that is the strategy we are sticking to that, apart from the cancer that trial that we all know is NRC-2694.
Sir, will it be fair to assume that ex -Revlimid our operating margins would be around 18% to 20%?
Yes, whatever other business we are doing. Because, I mean, the numbers talk to me as if I think we are doing like an 18% operating margin if I remove the R&D that you talk about because this quarter is like ex-Revlimid, right?